Does your child have ADHD or vision problems? Optometrist says both share similar symptoms
Neuro-optometrist Dr. Bryce Appelbaum, a Maryland-based doctor board certified in vision therapy and graduate of the Illinois College of Optometry, says an ADHD diagnosis isn't complete without ruling out a functional vision problem.
"Symptoms of ADD or ADHD and functional vision problems are so, so similar," he said. "If our eyes can't coordinate together as a team. If the inside muscles of the eyes are having a hard time focusing and making something clear and keeping it clear, from difficulty tracking our eyes, it's so much harder to sustain visual attention than it should be, and our mind's ability to stay focused is deeply embedded in our eye's ability to stay focused."
So, how can this impact a child's behavior?
"A child who is squirmy with desk work, loses their place with reading or prefers to rely on their ears rather than their eyes in the classroom setting or reading at home with mom or dad, those are clear signs of a functional vision problem impacting their ability to use their eyes together," Dr. Appelbaum said.
For parents and teachers, Dr. Appelbaum says they can start assessing the child by looking at their performance.
"A smart child whose performance drops throughout the day, or a child who is avoiding reading, preferring to be read to, or a child whose even having a hard time maintaining eye contact. Those are clear signs that vision is not guiding, leading and isn't developed like it's intended to."
Dr. Appelbaum says research shows one in 10 kids has a vision problem significant enough to impact learning. More than 80 percent of what a child learns in the classroom comes through the visual processing of information.
For more about functional vision problems, follow Dr. Appelbaum on
. Additional information can be found online at
MyVisionFirst
and
ScreenFit
.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
HealthPartners launches simple, copay-only health plan
Simplica NextGen Copay plan provides costs up front, lets members compare providers, and can save employers up to 15% compared to other plan options. BLOOMINGTON, Minn., August 14, 2025--(BUSINESS WIRE)--HealthPartners is launching a variable copay benefit plan that aims to provide unparalleled transparency of cost and coverage to members. HealthPartners Simplica NextGen Copay health plan has no deductible or coinsurance for in-network care, and members see what they'll pay up front before scheduling. Copay amounts for specific services at each hospital or clinic vary based on the quality and affordability of the care delivered. A key feature of the plan is the personalized digital experience fully integrated within a member's HealthPartners account. Using HealthPartners' Find Care tool, members can search by condition, provider or service; compare care options; and see their exact copay before scheduling. Members pay less when they choose care with better outcomes. "We developed Simplica in response to the growing demand for more predictable benefits," says Andrea Walsh, HealthPartners president and CEO. "This plan gives members the cost clarity and ease they expect from their health plan and guides them in making informed decisions about where to get the care they need." For example, the copay for an office visit will range from $20 to $150 depending upon the plan option, care site and service. Most same day labs and x-rays are bundled into the copay – helping reduce unexpected costs. Services that may require a separate copay are also visible through the Find Care digital experience. In addition, many virtual care options are covered at a $0 copay. The plan will launch Jan. 1, 2026, and is initially available to large-group, self-insured employers in the Twin Cities metro and surrounding counties. Simplica can save companies up to 15% in claim costs and that translates into savings for employees. "Unlike third-party platforms or standalone applications, Simplica delivers one seamless experience that makes it easier for members and employers to understand and manage costs," says Moe Suleiman, HealthPartners senior vice president of health solutions. "This plan ties copays to provider value, guides members in real time, and delivers the digital-first convenience today's workforce expects." For more information, visit the Simplica NextGen Copay website. About HealthPartners HealthPartners is a nonprofit organization with a mission of improving health and well-being in partnership with its members, patients and community. An integrated system of care and coverage since its founding in 1957, HealthPartners operates hospitals and clinics, health plans, and a research and education institute. The Minneapolis-based organization serves more than 1.3 million patients in Minnesota and Wisconsin and 1.7 million medical and dental health plan members nationwide. For more information, visit View source version on Contacts Amanda
Business Wire
a minute ago
- Business Wire
HealthPartners launches simple, copay-only health plan
BLOOMINGTON, Minn.--(BUSINESS WIRE)--HealthPartners is launching a variable copay benefit plan that aims to provide unparalleled transparency of cost and coverage to members. 'We developed Simplica in response to the growing demand for more predictable benefits.' -Andrea Walsh, HealthPartners president and CEO Share HealthPartners Simplica NextGen Copay health plan has no deductible or coinsurance for in-network care, and members see what they'll pay up front before scheduling. Copay amounts for specific services at each hospital or clinic vary based on the quality and affordability of the care delivered. A key feature of the plan is the personalized digital experience fully integrated within a member's HealthPartners account. Using HealthPartners' Find Care tool, members can search by condition, provider or service; compare care options; and see their exact copay before scheduling. Members pay less when they choose care with better outcomes. 'We developed Simplica in response to the growing demand for more predictable benefits,' says Andrea Walsh, HealthPartners president and CEO. 'This plan gives members the cost clarity and ease they expect from their health plan and guides them in making informed decisions about where to get the care they need.' For example, the copay for an office visit will range from $20 to $150 depending upon the plan option, care site and service. Most same day labs and x-rays are bundled into the copay – helping reduce unexpected costs. Services that may require a separate copay are also visible through the Find Care digital experience. In addition, many virtual care options are covered at a $0 copay. The plan will launch Jan. 1, 2026, and is initially available to large-group, self-insured employers in the Twin Cities metro and surrounding counties. Simplica can save companies up to 15% in claim costs and that translates into savings for employees. 'Unlike third-party platforms or standalone applications, Simplica delivers one seamless experience that makes it easier for members and employers to understand and manage costs,' says Moe Suleiman, HealthPartners senior vice president of health solutions. 'This plan ties copays to provider value, guides members in real time, and delivers the digital-first convenience today's workforce expects.' For more information, visit the Simplica NextGen Copay website. About HealthPartners HealthPartners is a nonprofit organization with a mission of improving health and well-being in partnership with its members, patients and community. An integrated system of care and coverage since its founding in 1957, HealthPartners operates hospitals and clinics, health plans, and a research and education institute. The Minneapolis-based organization serves more than 1.3 million patients in Minnesota and Wisconsin and 1.7 million medical and dental health plan members nationwide. For more information, visit
Yahoo
24 minutes ago
- Yahoo
Which Gene Therapy Technology Wins? New Data from Spherix Global Insights Reveals Emerging Hematologist Preferences in Beta Thalassemia Care
New research from Spherix Global Insights reveal Vertex/CRISPR Therapeutics' Casgevy holding a competitive edge over bluebird bio's Zynteglo as preferred beta thalassemia gene therapies. EXTON, PA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within the hematology community: whether the future belongs to gene editing or gene addition. Recent physician survey data from Market DynamixTM: Transfusion-Dependent Thalassemia reveal a clear shift in preference toward the CRISPR/Cas9-based therapy Casgevy with half of hematologists now favoring it, compared to just one-fifth for Zynteglo, a lentiviral vector-based therapy. The remaining respondents express no strong preference, citing similar efficacy and safety profiles in clinical trials. Casgevy (exagamglogene autotemcel, Vertex/CRISPR Therapeutics) uses CRISPR/Cas9 gene editing to disable the BCL11A enhancer, reactivating the body's natural production of fetal hemoglobin (HbF) – an oxygen-carrying molecule that can compensate for defective β-globin. 'Potential for more efficient editing and promising efficacy data,' one physician noted, adding that Casgevy's 'novel CRISPR platform' and accumulating real-world experience were compelling advantages. Zynteglo (betibeglogene autotemcel, bluebird bio) takes a different approach: inserting a functional HBB (β-globin) gene into a patient's hematopoietic stem cells via a lentiviral vector, restoring normal hemoglobin production. Physicians highlight its 'higher rate of transfusion independence (90–95% in long-term studies),' 'well-established safety profile,' and 'durable results' as support for their preference. While some clinicians see Casgevy as a leap forward in precision and efficiency, others value Zynteglo's longer track record and direct β-globin restoration. For many, the choice remains personalized, depending on patient genotype, treatment center expertise, insurance coverage, and patient or family comfort with each technology. Despite the promise of both therapies, physicians in suburban and rural areas report that demand for gene therapy exceeds available capacity. In addition, hematologists in the south and west are more likely to cite physical distance to certified gene therapy centers as a barrier. Even when centers are accessible, high upfront costs, lengthy insurance approvals, and constrained treatment slots can delay care. TDT is a severe inherited blood disorder requiring lifelong blood transfusions and iron chelation therapy. Gene therapy offers the potential for transfusion independence, but equitable access remains a critical challenge. Spherix will continue to monitor the hemoglobinopathy market, including thalassemia, through annual Market DynamixTM and Patient Chart DynamixTM services. Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the service evaluates current treatment approaches, unmet needs, and likely impact of pipeline agents over a three-to-five-year horizon. Patient Chart Dynamix™ is an independent service that includes robust patient chart audits and integrated specialist surveys fielded biannually. This research provides an in-depth, real-world view of treatment practices by combining verified patient data with attitudinal insights from physicians. The series highlights clinical decision-making, treatment sequencing, and outcomes for targeted patient populations across key therapeutic areas. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: Spherix Global Insights Contacts Sarah Hendry, Hematology Franchise Head NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284
